The global over-the-counter (OTC) pain medication market is poised for steady growth, with its market size expected to attain ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

Pfizer has won European Commission approval of ... or syringe for those with severe hemophilia A or B. The U.S. Food and Drug Administration approved Hympavzi in October.

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for ...

With Pfizer having recently scored an approval for ... Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to inhibit activated ...

In 2023, the then 49-year-old went to her physician with painful headaches, blurring vision, pain and swelling of her eyes ...

Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...